Pulse Biosciences Inc (PLSE) wrapped up enrollment in its NanoPulse AF pivotal IDE study three months early while reporting a wider GAAP net loss of $23.1 million and roughly two years of cash runway.
HAYWARD, Calif., October 22, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.
Pulse Biosciences (PLSE) has an average rating of buy and mean price target of $62.33, according to
Pulse Biosciences recently announced that its pivotal NANOPULSE-AF Study has reached full enrollment of 164 evaluable patients across 15 sites, and its latest nPulse technology for ventricular arrhythmias was featured at the now-completed 21st Annual International Ventricular Arrhythmias Symposium in New York. Together, these updates highlight growing clinical and physician engagement around the nPulse platform, potentially strengthening the company’s position in emerging pulse field...
HAYWARD, Calif., October 08, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York.
The fair value estimate for Pulse Biosciences has shifted from US$45.25 to US$54.00 per share, which is about a 19% move in the underlying price target framework. Analysts link this change to fresh enthusiasm around the company’s nsPFA technology, first in human European data, and upcoming clinical and regulatory milestones that could influence how investors frame long term potential. In the sections that follow, you will see how these factors shape the current narrative and how to track it...
PLSE’s catheter data and rapid pivotal enrollment showcase that they have a healthy and promising business. I reiterate my “Hold” on PLSE at these levels.
Pulse Biosciences (PLSE) has an average rating of buy and mean price target of $54, according to ana
Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.
Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.
HAYWARD, Calif., September 15, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sara
Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.
The medical device maker now has a new bull touting its growth potential.
The medical device maker now has a new bull touting its growth potential.
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
This is the newest page. Registered accounts read further back.